These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27021610)

  • 21. The status of proton pump inhibitor use: a prescription survey of 45 hospitals in China.
    Ying J; Li LC; Wu CY; Yu ZW; Kan LD
    Rev Esp Enferm Dig; 2019 Oct; 111(10):738-743. PubMed ID: 31373505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of proton pump inhibitors in children: a comprehensive review.
    Gibbons TE; Gold BD
    Paediatr Drugs; 2003; 5(1):25-40. PubMed ID: 12513104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel.
    Furuta T; Sugimoto M; Kodaira C; Nishino M; Yamade M; Uotani T; Sahara S; Ichikawa H; Kagami T; Iwaizumi M; Hamaya Y; Osawa S; Sugimoto K; Umemura K
    J Thromb Thrombolysis; 2017 Apr; 43(3):333-342. PubMed ID: 27981489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safe use of proton pump inhibitors in patients with cirrhosis.
    Weersink RA; Bouma M; Burger DM; Drenth JPH; Harkes-Idzinga SF; Hunfeld NGM; Metselaar HJ; Monster-Simons MH; van Putten SAW; Taxis K; Borgsteede SD
    Br J Clin Pharmacol; 2018 Aug; 84(8):1806-1820. PubMed ID: 29688583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
    Remák E; Brown RE; Yuen C; Robinson A
    Curr Med Res Opin; 2005 Oct; 21(10):1505-17. PubMed ID: 16238890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of reflux esophagitis: does the choice of proton pump inhibitor matter?
    Labenz J; Armstrong D; Leodolter A; Baldycheva I
    Int J Clin Pract; 2015 Jul; 69(7):796-801. PubMed ID: 25721889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period.
    Haastrup PF; Paulsen MS; Christensen RD; Søndergaard J; Hansen JM; Jarbøl DE
    Aliment Pharmacol Ther; 2016 Jul; 44(1):78-87. PubMed ID: 27137875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
    Funck-Brentano C; Szymezak J; Steichen O; Ducint D; Molimard M; Remones V; Azizi M; Gaussem P
    Arch Cardiovasc Dis; 2013 Dec; 106(12):661-71. PubMed ID: 24246616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical pharmacological aspects of the proton pump inhibitor therapy: importance of pharmacogenetic differences in the clinical practice].
    Mullner K; Molnar B; Tulassay Z
    Orv Hetil; 2007 Mar; 148(12):543-51. PubMed ID: 17444020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
    Robinson M
    Eur J Gastroenterol Hepatol; 2001 May; 13 Suppl 1():S43-7. PubMed ID: 11430508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling.
    Johnson DA; Chilton R; Liker HR
    Postgrad Med; 2014 May; 126(3):239-45. PubMed ID: 24918808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3.
    Narumi K; Sato Y; Kobayashi M; Furugen A; Kasashi K; Yamada T; Teshima T; Iseki K
    Biopharm Drug Dispos; 2017 Dec; 38(9):501-508. PubMed ID: 28801980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study.
    Sakurai Y; Mori Y; Okamoto H; Nishimura A; Komura E; Araki T; Shiramoto M
    Aliment Pharmacol Ther; 2015 Sep; 42(6):719-30. PubMed ID: 26193978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis.
    Kwok CS; Jeevanantham V; Dawn B; Loke YK
    Int J Cardiol; 2013 Aug; 167(3):965-74. PubMed ID: 22464478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Practical considerations in the management of proton-pump inhibitors.
    Aguilera-Castro L; Martín-de-Argila-dePrados C; Albillos-Martínez A
    Rev Esp Enferm Dig; 2016 Mar; 108(3):145-53. PubMed ID: 26666270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
    Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
    J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
    Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating the Effect of Six Proton Pump Inhibitors on the Antiplatelet Effects of Clopidogrel.
    Przespolewski ER; Westphal ES; Rainka M; Smith NM; Bates V; Gengo FM
    J Stroke Cerebrovasc Dis; 2018 Jun; 27(6):1582-1589. PubMed ID: 29449127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Esomeprazole and rabeprazole did not reduce antiplatelet effects of aspirin/clopidogrel dual therapy in patients undergoing percutaneous coronary intervention: a prospective, randomized, case-control study.
    Liu LP; Wang Y; Si R; Yuan M; Cheng K; Guo WY
    Expert Opin Pharmacother; 2016; 17(1):7-16. PubMed ID: 26549402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis.
    Giuliano C; Wilhelm SM; Kale-Pradhan PB
    Expert Rev Clin Pharmacol; 2012 May; 5(3):337-44. PubMed ID: 22697595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.